Comparison between Deferoxamine and Combined Therapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients

AUTHORS

A Tamaddoni 1 , MS Ramezani 2 , *

1 Amirkola Thalassemia Center, Babol University of Medical Sciences, Mazandaran, Iran

2 Amirkola Thalassemia Center, Babol University of Medical Sciences, [email protected], Mazandaran, Iran

How to Cite: Tamaddoni A, Ramezani M. Comparison between Deferoxamine and Combined Therapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients, Iran Red Crescent Med J. Online ahead of Print ; 12(6):655-659.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 12 (6); 655-659
Article Type: Brief Report
Received: December 20, 2009
Accepted: April 12, 2010

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Iron overload is the main cause of morbidity and mortality in patients with beta thalassemia major. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The combined treatment with deferoxamine and deferiprone could have an increased chelation efficacy and allow drug doses and toxicity to be reduced.

 

Methods: Eighty patients with thalassemia major were randomized to receive one of the treatments: deferoxamine given in combination with deferiprone and deferoxamine alone. Changes in serum ferritin and any toxicity were determined.

 

Results: After one year, the mean serum ferritin (±SD) in deferoxamine alone group decreased from 2945 (±591) ng/ml to 2,451 (±352) ng/ml (p<0.001). In the group treat with deferoxamine and deferiprone, a dramatical decline was noticed from 2986 (±612) ng/ml to 2,082 (±221) ng/ml (p<0.001). A significant improvement was observed after 6 months of combination therapy. The main side-effects were skin reactions (deferoxamine alone), nausea and arthralgia (combined therapy).

 

Conclusion: Combination therapy is a practical and effective procedure to decrease severe iron overload in patients with beta thalassemia major.

Keywords

Thalassemia major Deferoxamine Deferiprone Chelation therapy

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: